The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparison of clinical outcomes of stable disease with confirmed tumor reduction and RECIST partial response for tebentafusp in metastatic uveal melanoma (mUM).
 
Alexandra Ikeguchi
Research Funding - BioNTech SE (Inst); Immunocore (Inst); Merck (Inst); Regeneron (Inst)
 
Takami Sato
Consulting or Advisory Role - Immunocore, Castle Biosciences
Research Funding - Immunocore, Verastem. (Inst)
 
Marcus O. Butler
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Roche; Sanofi
Consulting or Advisory Role - Adaptimmune; Adaptimmune; Bristol-Myers Squibb; EMD Serono; Genzyme; GlaxoSmithKline; GlaxoSmithKline; IDEAYA Biosciences; Immunocore; Immunovaccine; Instil Bio; Iovance Biotherapeutics; LaRoche Posay; Medison; Merck; Novartis; Pfizer; Regeneron; Sanofi; Sun Pharma
Research Funding - Merck (Inst); Novartis Canada Pharmaceuticals Inc (Inst); Takara Bio (Inst)
Expert Testimony - Merck
 
Richard D. Carvajal
Consulting or Advisory Role - Alkermes; Aura Biosciences; Bristol-Myers Squibb/Celgene; Castle Biosciences; Chimeron Bio; Delcath Systems; Genzyme; Hengrui Pharmaceutical; IDEAYA Biosciences; Immunocore; InxMed; Iovance Biotherapeutics; Merck; Oncosec; Pierre Fabre; PureTech; Regeneron; Rgenix; Sorrento Therapeutics; TriSalus Life Sciences
Speakers' Bureau - Bristol-Myers Squibb/Medarex
Research Funding - Amgen (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Incyte (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
 
Joseph J Sacco
Honoraria - Immunocore
Consulting or Advisory Role - BMS; Immunocore; Immunocore (Inst); MSD
Research Funding - AstraZeneca (Inst); BMS (Inst); Immunocore (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - BMS; MSD
 
Alexander Noor Shoushtari
Consulting or Advisory Role - Bristol-Myers Squibb; Erasca, Inc; Novartis
Research Funding - Alkermes (Inst); Bristol-Myers Squibb; Checkmate Pharmaceuticals (Inst); Foghorn Therapeutics (Inst); Immunocore; Iovance Biotherapeutics (Inst); Linnaeus Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Targovax (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Jessica Cecile Hassel
Honoraria - Amgen; BMS GmbH & Co. KG; Bristol Myers Squibb Foundation; GlaxoSmithKline; Immunocore; MSD; Novartis; Pierre Fabre; Sanofi; Sun Pharma
Consulting or Advisory Role - BMS GmbH & Co. KG (Inst); GlaxoSmithKline; Immunocore (Inst); MSD; Novartis (Inst); Onkowissen; Philogen (Inst); Pierre Fabre; Sanofi Aventis GmbH (Inst); Sun Pharma
Research Funding - 4SC (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Genmab (Inst); Idera (Inst); immatics (Inst); Immunocore (Inst); IO Biotech (Inst); Iovance Biotherapeutics (Inst); Nektar (Inst); Novartis (Inst); Philogen (Inst); Pierre Fabre (Inst); Regeneron (Inst); Replimune (Inst); Sanofi (Inst); Sanofi Aventis GmbH (Inst); Sun Pharma (Inst)
Travel, Accommodations, Expenses - BMS GmbH & Co. KG; Iovance Biotherapeutics; Sun Pharma
 
Paul D. Nathan
Consulting or Advisory Role - 4SC; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Immunocore; Ipsen; Merck; MSD; Novartis; Pfizer; Pierre Fabre
Speakers' Bureau - Bristol-Myers Squibb; Merck; MSD; Novartis
Research Funding - Immunocore (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Immunocore; MSD
 
Josep M. Piulats
Research Funding - BeiGene, BMS, Immunocore, Mirati, MSD
 
Douglas Buckner Johnson
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck; Mosaic ImmunoEngineering; Novartis; Pfizer; Targovax
Research Funding - Bristol-Myers Squibb; Incyte
Patents, Royalties, Other Intellectual Property - Abatacept for the use of immune related adverse events.; Intellectual property and patents pending surrounding use of MHC-II and response to immune therapy
 
Jason J. Luke
Stock and Other Ownership Interests - Actym Therapeutics; Alphamab; Arch Oncology; Kanaph Therapeutics; Mavu Pharmaceutical; NeoTX; NeoTX; Onc.AI; Pyxis; STipe Therapeutics; Tempest Therapeutics
Consulting or Advisory Role - 7 Hills Pharma; Abbvie; Alnylam; Alphamab; Bayer; Bright Peak Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Codiak Biosciences; Crown Bioscience; CStone Pharmaceuticals; Day One Therapeutics; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Genentech; Gilead Sciences; Hotspot Therapeutics; Immunocore; Incyte; Inzen Therapeutics; Janssen; Kadmon; KSQ Therapeutics; Merck; Nektar; Novartis; Onc.AI; Partner Therapeutics; Pfizer; Reflexion Medical; Regeneron; Ribon Therapeutics; Rubius Therapeutics; SERVIER; Silicon Therapeutics; STINGthera; STipe Therapeutics; Synlogic; Synthekine; Tempest Therapeutics; Tesaro; TRex Bio; Werewolf Therapeutics; Xencor; Xilio Therapeutics
Research Funding - Abbvie (Inst); Agios (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); EMD Serono (Inst); Fstar (Inst); Genmab (Inst); Ikena Oncology (Inst); Immatics (Inst); Incyte (Inst); Kadmon (Inst); KAHR Medical (Inst); Macrogenics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Nektar (Inst); NextCure (Inst); Numab (Inst); Replimune (Inst); Rubius Therapeutics (Inst); Scholar Rock (Inst); Spring bank (Inst); Synlogic (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Trishula Therapeutics (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Janssen; Merck; Mersana; Novartis; Pyxis; Reflexion Medical; Xilio Therapeutics
 
Enrique Espinosa
Consulting or Advisory Role - BMS, MSD, Novartis, Pierre Fabre; non-remunerated activities: Vice-President (Grupo Espanol Melanoma);
Speakers' Bureau - BMS, MSD, Novartis, Pierre Fabre.
 
Serge Leyvraz
Honoraria - Bayer
Consulting or Advisory Role - Bayer
Travel, Accommodations, Expenses - Bayer
 
Laura Collins
Employment - Immunocore
Stock and Other Ownership Interests - Immunocore
 
Ramakrishna Edukulla
Employment - Immunocore
Stock and Other Ownership Interests - Immunocore
 
Piruntha Thiyagarajah
Employment - Immunocore; Reckitt Benckiser (I)
Stock and Other Ownership Interests - AstraZeneca/MedImmune
 
Omid Hamid
Stock and Other Ownership Interests - Bactonix
Honoraria - Bristol-Myers Squibb; Immunocore; Novartis; Pfizer; Regeneron
Consulting or Advisory Role - Alkermes; Amgen; Bactonix; BeiGene; BioAtla; Bristol-Myers Squibb; Eisai; Genentech; Georgiamune; GigaGen; GlaxoSmithKline; Grit Biotechnology; Idera; Immunocore; Incyte; Instil Bio; IO Biotech; Iovance Biotherapeutics; Janssen; KSQ Therapeutics; Merck; Moderna Therapeutics; NGM Biopharmaceuticals; Novartis; Obsidian Therapeutics; Pfizer; Regeneron; Roche; Sanofi; Seagen; Tempus; Vial; Zelluna
Speakers' Bureau - Bristol-Myers Squibb; Immunocore; Novartis; Pfizer; Regeneron
Research Funding - Aduro Biotech (Inst); Akeso Biopharma (Inst); Amgen (Inst); Arcus Biosciences (Inst); Bioatla (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Merck Serono (Inst); Moderna Therapeutics (Inst); NextCure (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Torque (Inst); Zelluna (Inst)